Trellis Bioscience
US-based Trellis Bioscience develops therapeutic antibody treatments for infectious diseases and cancer.
Founded
1998US-based Trellis Bioscience develops therapeutic antibody treatments for infectious diseases and cancer.
Founded in Menlo Park, Trellis Bioscience is a biotechnology company dedicated to developing therapeutic antibody treatments for infectious diseases and cancer. The company's core mission is to harness the power of native human monoclonal antibodies to combat severe health conditions, aiming to improve patient outcomes and advance global health. Trellis Bioscience's product pipeline includes innovative treatments targeting bacteria, viruses, and oncology indications.
Notable figures affiliated with Trellis Bioscience include a distinguished management team and board of directors with extensive experience in biotechnology and pharmaceuticals. The company has received significant recognition, including FDA Fast Track and QIDP designations for its TRL1068 antibody, underscoring its commitment to addressing urgent medical needs. Trellis Bioscience's pioneering work has made a substantial impact in the fields of infectious diseases and oncology, positioning it as a leader in therapeutic antibody development.
Companies similar to Trellis Bioscience include TrueBinding, Trelys, Treeline Biosciences and Dren Bio.
Trellis Bioscience was founded in 1998.
Trellis Bioscience's headquarters is located in San Francisco, CA, US.
Trellis Bioscience's most recent funding round was for $3.2M (USD) in October 2019.
As of Oct 1, 2019, Trellis Bioscience has disclosed funding of $28.6M (USD). Undisclosed round amounts are excluded.
Trellis Bioscience has 75 employees as of Feb 5, 2024.
Dren Bio
drenbio.com
